慢性乙型肝炎肝纤维化/肝硬化的治疗现状

钱建丹; 赵鸿; 王贵强

doi:10.3969/j.issn.1001-5256.2021.12.036

慢性乙型肝炎肝纤维化/肝硬化的治疗现状

DOI: 10.3969/j.issn.1001-5256.2021.12.036

北京大学第一医院感染疾病科暨肝病中心，北京 100034

基金项目:

国家科技部传染病重大专项 (2017ZX10203202)

详细信息

通信作者:
王贵强，john131212@126.com

中图分类号: R512.62;R575.2
计量
- 文章访问数: 638
- HTML全文浏览量: 158
- PDF下载量: 134
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-08
- 录用日期: 2021-06-11
- 出版日期: 2021-12-20

Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis

Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China

Research funding:

China Mega-Project for Infectious Diseases (2017ZX10203202)

摘要

摘要: 慢性乙型肝炎(CHB)肝纤维化是HBV感染所导致的肝组织损伤和修复过程, 严重者发展成肝硬化，目前仍未有特效治疗药物。本文归纳了CHB肝纤维化发生发展过程中涉及的主要机制靶点如肝星状细胞活化、炎症、肠肝轴等，以及与纤维化相关的信号转导通路。靶向这些靶点可能对抗纤维化治疗有一定作用。目前抗HBV治疗联合或序贯中药抗纤维化治疗可使一部分患者的肝纤维化/肝硬化得以延缓甚至逆转，但逆转晚期肝纤维化/肝硬化仍面临很大的挑战，且联合或序贯治疗的时机仍无共识。探索与CHB肝纤维化/肝硬化高度相关的治疗靶标，结合靶向多种纤维化进展途径的化合物的组合疗法将成为未来研究的重点。
- 乙型肝炎, 慢性 /
- 肝硬化 /
- 治疗学
Abstract: Chronic hepatitis B (CHB) liver fibrosis is the process of liver tissue damage and repair caused by hepatitis B virus (HBV) infection and may develop into liver cirrhosis in severe cases, and there are still no specific drugs for the treatment of this disease. This article summarizes the main targets involved in the development and progression of CHB liver fibrosis, such as hepatic stellate cell activation, inflammation, and gut-liver axis, as well as the signal transduction pathways associated with fibrosis, and targeting these targets may have a certain anti-fibrogenic effect. At present, anti-HBV therapy combined with or followed by anti-fibrotic therapy can delay or even reverse liver fibrosis/cirrhosis in some patients; however, the reversal of advanced liver fibrosis/cirrhosis still faces great challenges, and there is still no consensus on the timing of combined or sequential therapy. It is believed that identification of therapeutic targets highly associated with CHB liver fibrosis/cirrhosis and combination therapy with compounds targeting multiple pathways associated with liver fibrosis will become the focus of future research.
- Hepatitis B, Chronic /
- Liver Cirrhosis /
- Therapeutics

HTML全文

表 1 NAs或IFNα逆转CHB肝纤维化/肝硬化相关研究

研究类型	研究人群	组别	干预措施	例数	疗程	逆转定义	逆转率(%)	病理评估方法
长期累积研究^[23]	初治CHB, 显著肝纤维化/肝硬化	-	ETV	10	267~297周	评分减少≥1	100	Ishak
开放标签研究^[24]	CHB肝纤维化(82%)/肝硬化(18%)	-	ETV	57(10^*)	280周(3~7年)	评分减少≥1	88(100^*)	Ishak
开放标签研究^[25]	CHB肝纤维化/代偿期肝硬化	-	ETV	167	120~148周	评分减少≥1	63	Knodel
多中心前瞻性研究^[26]	初治CHB	-	ETV	120	78周	评分减少≥1	45	METAVIR和FibroScan
开放标签前瞻性研究^[27]	CHB明显肝纤维化/ 肝硬化	-	TDF	133(96^*)	260周	评分减少≥1	68(74^*)	Ishak
Meta分析^[28] (13项研究)	CHB肝纤维化/肝硬化	观察组	IFNα-2a/2b或PEG-IFN	707	48~332周	评分减少≥1	0~44	METAVIR/Ishak
		对照组	未治疗	787	-		0~22
注：*肝硬化患者。

下载: 导出CSV

参考文献(45)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	VITTAL A, GHANY MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: A US perspective[J]. Clin Liver Dis, 2019, 23(3): 417-432. DOI: 10.1016/j.cld.2019.04.008.
[3]	YOON YJ, FRIEDMAN SL, LEE YA. Antifibrotic therapies: Where are we now?[J]. Semin Liver Dis, 2016, 36(1): 87-98. DOI: 10.1055/s-0036-1571295.
[4]	ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875. DOI: 10.3390/cells9040875.
[5]	HENDERSON NC, RIEDER F, WYNN TA. Fibrosis: From mechanisms to medicines[J]. Nature, 2020, 587(7835): 555-566. DOI: 10.1038/s41586-020-2938-9.
[6]	LEVRERO M, ZUCMAN-ROSSI J. Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64(1 Suppl): S84-S84, S101. DOI: 10.1016/j.jhep.2016.02.021.
[7]	GONG J, TU W, HAN J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx[J]. Sci Rep, 2016, 6: 37717. DOI: 10.1038/srep37717.
[8]	LIU X, ZHU ST, YOU H, et al. Hepatitis B virus infects hepatic stellate cells and affects their proliferation and expression of collagen type I[J]. Chin Med J (Engl), 2009, 122(12): 1455-1461. http://www.cqvip.com/QK/85656X/200912/30712357.html
[9]	KRENKEL O, TACKE F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17(5): 306-321. DOI: 10.1038/nri.2017.11.
[10]	WYNN TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases[J]. J Clin Invest, 2007, 117(3): 524-529. DOI: 10.1172/JCI31487.
[11]	LUEDDE T, KAPLOWITZ N, SCHWABE RF. Cell death and cell death responses in liver disease: Mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147(4): 765-783. e4. DOI: 10.1053/j.gastro.2014.07.018.
[12]	MENG F, WANG K, AOYAMA T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J]. Gastroenterology, 2012, 143(3): 765-776. e3. DOI: 10.1053/j.gastro.2012.05.049.
[13]	CHEN DB, WANG K, WANG HN, et al. Therapeutic potential of human umbilical cord-derived mesenchy-mal stem cells in the treatment of CCl₄ induced liver fibrosis[J]. Letters in Biotechnology, 2013, 3: 347-350. DOI: 10.3969/j.issn.1009-0002.2013.03.011. 陈冬波, 王科, 王慧娜, 等. 人脐带间充质干细胞对CCl₄诱导肝纤维化的治疗作用研究[J]. 生物技术通讯, 2013, 3: 347-350. DOI: 10.3969/j.issn.1009-0002.2013.03.011.
[14]	WANG J, WANG Y, ZHANG X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients[J]. Front Microbiol, 2017, 8: 2222. DOI: 10.3389/fmicb.2017.02222.
[15]	CHOU HH, CHIEN WH, WU LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112(7): 2175-2180. DOI: 10.1073/pnas.1424775112.
[16]	TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65(12): 2035-2044. DOI: 10.1136/gutjnl-2016-312729.
[17]	CHAUHAN A, KUMAR R, SHARMA S, et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: A pilot study[J]. Dig Dis Sci, 2021, 66(3): 873-880. DOI: 10.1007/s10620-020-06246-x.
[18]	YING HZ, CHEN Q, ZHANG WY, et al. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)[J]. Mol Med Rep, 2017, 16(6): 7879-7889. DOI: 10.3892/mmr.2017.7641.
[19]	DEWIDAR B, MEYER C, DOOLEY S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8(11). DOI: 10.3390/cells8111419.
[20]	IVANOV AV, VALUEV-ELLISTON VT, TYURINA DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis[J]. Oncotarget, 2017, 8(3): 3895-3932. DOI: 10.18632/oncotarget.13904.
[21]	NISHIKAWA K, OSAWA Y, KIMURA K. Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs[J]. Int J Mol Sci, 2018, 19(10). DOI: 10.3390/ijms19103103.
[22]	ROCKEY DC. Liver fibrosis reversion after suppression of hepatitis B virus[J]. Clin Liver Dis, 2016, 20(4): 667-679. DOI: 10.1016/j.cld.2016.06.003.
[23]	SCHIFF ER, LEE SS, CHAO YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2011, 9(3): 274-276. DOI: 10.1016/j.cgh.2010.11.040.
[24]	CHANG TT, LIAW YF, WU SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-893. DOI: 10.1002/hep.23785.
[25]	YOKOSUKA O, TAKAGUCHI K, FUJIOKA S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection[J]. J Hepatol, 2010, 52(6): 791-799. DOI: 10.1016/j.jhep.2009.12.036.
[26]	WU SD, LIU LL, CHENG JL, et al. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment[J]. Clin Exp Med, 2018, 18(3): 433-443. DOI: 10.1007/s10238-018-0501-x.
[27]	MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475. DOI: 10.1016/S0140-6736(12)61425-1.
[28]	POYNARD T, MASSARD J, RUDLER M, et al. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials[J]. Gastroenterol Clin Biol, 2009, 33(10-11): 916-922. DOI: 10.1016/j.gcb.2009.06.006.
[29]	ZOUTENDIJK R, REIJNDERS JG, ZOULIM F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut, 2013, 62(5): 760-765. DOI: 10.1136/gutjnl-2012-302024.
[30]	RAMACHANDRAN P, HENDERSON NC. Antifibrotics in chronic liver disease: Tractable targets and translational challenges[J]. Lancet Gastroenterol Hepatol, 2016, 1(4): 328-340. DOI: 10.1016/S2468-1253(16)30110-8.
[31]	WENG HL, CAI WM, LIU RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis[J]. World J Gastroenterol, 2001, 7(1): 42-48. DOI: 10.3748/wjg.v7.i1.42.
[32]	WU YJ, CAI WM, LI Q, et al. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection[J]. Hepatobiliary Pancreat Dis Int, 2011, 10(2): 151-157. DOI: 10.1016/s1499-3872(11)60024-6.
[33]	LI H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula[J]. J Ethnopharmacol, 2020, 251: 112442. DOI: 10.1016/j.jep.2019.112442.
[34]	CHEN LJ, TANG H. Meta-analysis of the efficacy of fufangbiejiaruangan tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. Gansu Med, 2018, 37(8): 678-680, 696. https://www.cnki.com.cn/Article/CJFDTOTAL-GSYY201808004.htm 陈丽津, 汤浩. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化疗效Meta分析[J]. 甘肃医药, 2018, 37(8): 678-680, 696. https://www.cnki.com.cn/Article/CJFDTOTAL-GSYY201808004.htm
[35]	RONG G, CHEN Y, YU Z, et al. Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blinded, placebo-controlled trial[J]. J Infect Dis, 2020. DOI: 10.1093/infdis/jiaa266.[Online ahead of print]
[36]	LIAO QY, GUAN R, JIANG YX, et al. Systematic evaluation of compound biejia ruangan tablets combined with entecavir in the treatment of chronic hepatitis B complicated with hepatic fibrosis[J]. Eval Anal Drug-Use Hosp China, 2019, 19(9): 1031-1038. DOI: 10.14009/j.issn.1672-2124.2019.09.002. 廖庆英, 关蓉, 蒋吟啸, 等. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型病毒性肝炎伴肝纤维化的系统评价[J]. 中国医院用药评价与分析, 2019, 19(9): 1031-1038. DOI: 10.14009/j.issn.1672-2124.2019.09.002.
[37]	LIU HL, LV J, ZHAO ZM, et al. Fuzhenghuayu decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis[J]. Sci Rep, 2019, 9(1): 18719. DOI: 10.1038/s41598-019-54663-4.
[38]	WANG QL, TAO YY, SHEN L, et al. Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-beta1/Smads signaling pathway[J]. J Chin Integr Med, 2012, 10(5): 561-568. DOI: 10.3736/jcim20120512. 王清兰, 陶艳艳, 沈丽, 等. 扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J]. 中西医结合学报, 2012, 10(5): 561-568. DOI: 10.3736/jcim20120512.
[39]	LIU P, HU YY, LIU C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J]. World J Gastroenterol, 2005, 11(19): 2892-2899. DOI: 10.3748/wjg.v11.i19.2892.
[40]	CHEN Y, ZHAO Z, FAN H, et al. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial[J]. Contemp Clin Trials Commun, 2020, 19: 100601. DOI: 10.1016/j.conctc.2020.100601.
[41]	MA X, LIAO QY, HE X, et al. Systematic review on fuzhenghuayu capsules combined with entecavir in the treatment of liver fibrosis induced by chronic hepatitis B[J]. Eval Anal Drug-Use Hosp China, 2019, 19(12): 1413-1419. DOI: 10.14009/j.issn.1672-2124.2019.12.002. 马骁, 廖庆英, 何璇, 等. 扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的系统评价[J]. 中国医院用药评价与分析, 2019, 19(12): 1413-1419. DOI: 10.14009/j.issn.1672-2124.2019.12.002.
[42]	CHEN PL, HUANG GY, CUI YY, et al. A meta-analysis of Fuzheng huayu capsule combined with entecavir in the treatment of hepatitis B cirrhosis[J]. Chin J Integr Tradit West Med Liver Diss, 2021, 31(1): 63-69. DOI: 10.3969/j.issn.1005-0264.2021.01.018. 陈鹏兰, 黄古叶, 崔亚运, 等. 扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎肝硬化的Meta分析[J]. 中西医结合肝病杂志, 2021, 31(1): 63-69. DOI: 10.3969/j.issn.1005-0264.2021.01.018.
[43]	HUANG ZQ. Meta-analysis of therapeutic effects of anluohuaxianwan on hepatic fibrosis[J]. Chin J Drug Evaln, 2015, (1): 41-44. DOI: 10.3969/j.issn.2095-3593.2015.01.013. 黄志巧. 安络化纤丸抗肝纤维化疗效的Meta分析[J]. 中国药物评价, 2015, (1): 41-44. DOI: 10.3969/j.issn.2095-3593.2015.01.013.
[44]	MIAO L, YANG WN, DONG XQ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009. 苗亮, 杨婉娜, 董晓琴, 等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]. 中华肝脏病杂志, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.
[45]	ZONG J, ZHOU JF. Effect of Anluo Hua Xian pill combined with pegylated interferon α-2a on liver function and liver fibrosis in patients with chronic hepatitis B with liver fibrosis[J]. J Clin Res, 2019, 36(4): 771-773. DOI: 10.3969/j.issn.1671-7171.2019.04.054. 宗杰, 周建飞. 安络化纤丸联合聚乙二醇干扰素α-2a对慢性乙肝肝纤维化患者肝功能及肝纤维化的影响[J]. 医学临床研究, 2019, 36(4): 771-773. DOI: 10.3969/j.issn.1671-7171.2019.04.054.